Novo Nordisk launched Wegovy in China to target obesity, competing with Eli Lilly. Costing 1,400 yuan, the drug helps users lose weight but has potential side effects and is not covered by healthcare.
Wegovy’s Launch in China
Novo Nordisk recently introduced its weight-loss drug, Wegovy, in the Chinese market following approval from local health authorities in June. This move sets the stage for heightened competition with Eli Lilly, whose own weight-loss treatment has also garnered approval but is yet to be released in China’s significant pharmaceutical sector.
Cost and Accessibility
Priced at 1,400 yuan (approximately $194) for a set of four injections, Wegovy offers a more affordable option in China compared to its U.S. pricing. However, patients will need to bear the full cost as the drug is currently not covered by the national healthcare insurance plan, posing a potential barrier to accessibility for some individuals.
Benefits and Side Effects
Wegovy’s efficacy in aiding weight loss, with potential for users to shed over 10% of their body weight, is attributed to its key ingredient semaglutide, which helps regulate appetite and satiety. Despite its global popularity, concerns have been raised about side effects like nausea and the risk of misuse, particularly among non-obese individuals. Healthcare professionals are advised to remain vigilant to ensure safe and appropriate usage of the drug.
Source : Wegovy: The Popular Weight-Loss Drug Now Available in China